However, multivariate analyses demonstrate a higher risk for patients expressing either RAN or TPX2 than for those expressing XPO7 (Table 2), suggesting a more significant contribution of RAN’s mitotic function to ovarian cancer progression than its nucleo-cytoplasmic function. Here, TPX2 is linked to ovarian carcinoma.